Autonomix Medical announced that it has been granted a new U.S. patent covering technologies for sensing, mapping, and selectively targeting nerves using its catheter-based neuromodulation platform. The patent further strengthens the company's intellectual property portfolio and supports the development of precision nerve-targeting therapies for cancer-related pain and other diseases. Key Highlights New U.S. Patent Granted: Expands Autonomix's intellectual property portfolio covering advanced catheter-based neuromodulation technologies. Precision Nerve Mapping: The patented technology is designed to sense, identify, map, and selectively target specific nerves, enabling more precise treatment while minimizing damage to surrounding healthy tissue. Focus on Cancer Pain: The platform is being developed to treat pancreatic cancer pain, an area with significant unmet medical need where existing pain management options are often limited. Broader Oncology Potential: Beyond pancreatic cancer, the technology may have future applications across other cancer-related pain conditions and additional diseases involving the peripheral nervous system. Technology Differentiation: Autonomix's platform combines high-resolution nerve sensing with targeted catheter-based treatment, aiming to improve procedural precision compared with conventional nerve ablation approaches.